Does Molina Healthcare Cover Wegovy?
The verdict
Conditional on most plans
Molina Healthcare, a Medicaid-first plan, covers Wegovy for weight loss only in the minority of states whose Medicaid program includes GLP-1 obesity coverage — 13 states as of January 2026. In most Molina states Wegovy for obesity is excluded, though a non-weight-loss FDA indication such as the cardiovascular indication may be covered.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Molina Healthcare using your member ID.
Key facts
As of January 2026, only 13 state Medicaid programs cover GLP-1s for obesity — down from 16 in October 2025 after California, New Hampshire, Pennsylvania, and South Carolina dropped coverage.
KFF, Medicaid Coverage of and Spending on GLP-1s, January 2026
Wegovy is FDA-approved for chronic weight management (BMI 30+, or 27+ with a weight-related comorbidity) and cardiovascular risk reduction — it is not a diabetes drug and cannot be covered through a diabetes benefit.
FDA, Wegovy (semaglutide) prescribing information
Molina Healthcare operates Medicaid managed-care plans across multiple states; Wegovy weight-loss coverage is entirely determined by the individual state Medicaid PDL, not by Molina's own formulary decisions.
Molina Healthcare state plan information
Medicare vs. commercial coverage
Whether Molina Healthcare covers Wegovy depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Molina operates Medicare Advantage-PD (MA-PD) plans in select markets. Under Medicare Part D, weight-loss coverage for Wegovy is excluded by federal statute — this applies to all Medicare plans including Molina's. The cardiovascular risk reduction indication is coverable under Part D with prior authorization for members with established CVD who are overweight or obese. The Medicare GLP-1 Bridge ($50 per month, launching July 1, 2026 through December 31, 2027) provides weight-loss access outside Part D for eligible members meeting BMI criteria; members already on a Part D-covered GLP-1 are ineligible. Medicare beneficiaries cannot use the NovoCare savings card.
Commercial / Employer
Group & marketplace plans
Molina's primary line of business is Medicaid managed care. Medicaid weight-loss Wegovy coverage is entirely state-dependent: as of January 2026, only 13 state Medicaid programs cover GLP-1s for obesity — the count fell from 16 in October 2025 after California, New Hampshire, Pennsylvania, and South Carolina dropped coverage; North Carolina dropped in October 2025 and reinstated in December 2025. Where covered (for example, Michigan Medicaid lists Wegovy as a preferred anti-obesity medication with prior authorization, quantity limits, and eligibility for members age 12 and older), nominal Medicaid cost-share applies. In states where obesity coverage is excluded, all states retain coverage of non-weight-loss FDA indications such as the cardiovascular indication. Molina has a limited commercial and ACA book; weight-loss coverage there is employer-dependent and generally excluded on ACA individual plans. Verify on your state-specific Molina PDL.
The 5 boxes you must tick to get approved
Commercial plans that will consider Wegovy require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
0 of 5 requirements selected. Meet all 5 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Wegovy actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
$1,349 per month (Novo Nordisk published list price for a 28-day supply)
List price with no coverage — before any manufacturer savings card.
With coverage
Medicaid nominal cost-share where covered (typically $0 to $4 per prescription depending on state). NovoCare self-pay program approximately $349 per month for standard injection doses where no Medicaid coverage exists.
Typical monthly copay once prior authorization is approved.
Bridge program
NovoCare Wegovy Savings Offer (as little as $25 per month for commercially insured members) is not available to Medicaid beneficiaries. From January 1, 2027, Novo Nordisk has announced a list-price reduction to approximately $675 per month.
Reduced copay through the assistance program, where eligible.
All figures are estimates. Actual Medicaid cost-share depends on your state's Molina plan rules. Verify on the state-specific Molina formulary or call Molina member services.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Find your state's Molina Medicaid PDL
Visit the Molina Healthcare website, select your state, and access the Medicaid preferred drug list or formulary. Search for Wegovy (semaglutide 2.4 mg) under anti-obesity medications. If it is not listed for obesity, your state does not currently cover it through Medicaid.
- 2
Ask your prescriber to confirm prior-authorization criteria
If your state Medicaid covers Wegovy for obesity, your prescriber will need to document your BMI, any qualifying comorbidities, and in some states, prior participation in a lifestyle program. Your provider can contact Molina's prior-authorization line for state-specific criteria.
- 3
Confirm whether a non-weight-loss indication applies
If your state excludes Wegovy for obesity but you have established cardiovascular disease and are overweight or obese, ask your provider whether the cardiovascular risk reduction indication qualifies you for coverage. All Molina states cover applicable non-weight-loss FDA indications.
Options if Molina Healthcare won't cover Wegovy
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
State Medicaid GLP-1 obesity coverage (13 states, January 2026)
Michigan, New York, Texas, and other states on the KFF 13-state list cover Wegovy for obesity with PA and quantity limits through Molina Medicaid. Check the current KFF Medicaid GLP-1 tracker and your state PDL — the list changes as states add or drop coverage.
Wegovy cardiovascular indication
If you have established cardiovascular disease and are overweight or obese, Wegovy's CV indication may be covered even in states where obesity coverage is excluded. Ask your provider about this pathway.
NovoCare self-pay
Novo Nordisk's NovoCare program offers approximately $349 per month for standard injection doses with no insurance. Introductory pricing of approximately $199 per month for starting doses (0.25/0.5 mg) is available for first two fills through December 31, 2026. Not available to Medicaid beneficiaries at government-program pricing.
Compounded semaglutide
Compounded semaglutide, available through licensed telehealth platforms, does not require Medicaid prior authorization. Starting from $49 per month. Compounded semaglutide is not the same medication as Wegovy and has not been approved by the FDA.
These options are listed for information only — your own clinician decides what is appropriate for you.
Frequently Asked Questions
Only in states where the state Medicaid program has included GLP-1s for obesity in its PDL — 13 states as of January 2026. Coverage is not a Molina decision; it is a state-government decision. If you are in a Molina state that does not cover GLP-1s for obesity, Molina Medicaid will not cover Wegovy for weight loss regardless of your clinical circumstances. Verify on your state-specific Molina formulary.
No. Wegovy (semaglutide 2.4 mg) is FDA-approved for chronic weight management and cardiovascular risk reduction, not for type 2 diabetes. Molina cannot approve Wegovy for a diabetes indication because it does not carry that FDA approval. Ozempic (semaglutide in lower doses) is the diabetes formulation. Attempting to route Wegovy through a diabetes benefit will result in denial.
Several states reduced or eliminated GLP-1 obesity coverage in 2025 and early 2026 due to budget pressures. California, New Hampshire, Pennsylvania, and South Carolina dropped coverage. North Carolina dropped coverage in October 2025 and reinstated it in December 2025. The KFF Medicaid GLP-1 tracker monitors current state coverage — check it for the most current state list before assuming your state remains covered.
Molina's MA-PD plans follow the same Medicare statute as all Part D plans: weight-loss coverage for Wegovy is prohibited. The cardiovascular risk reduction indication is coverable with prior authorization for members with established CVD who are overweight or obese. Starting July 1, 2026, the Medicare GLP-1 Bridge offers eligible MA beneficiaries Wegovy for weight loss at $50 per month outside the Part D benefit. Eligibility criteria and exclusions apply.
The Novo Nordisk published list price for Wegovy is approximately $1,349 per month for a 28-day supply. Novo Nordisk's NovoCare self-pay program reduces this to approximately $199 per month for starting doses (through December 31, 2026) and approximately $349 per month for standard injection doses. The NovoCare savings card (commercially insured, as little as $25 per month) is not available to Medicaid beneficiaries. Verify current pricing at novocare.com.
Related Articles
Does BCBS North Carolina Cover Wegovy? 2026 | Curex
BCBS North Carolina: NC State Health Plan dropped weight-loss GLP-1s in 2024; NC Medicaid removed obesity coverage October 2025. Verify your specific plan.
Read moreDoes Kaiser Permanente Cover Wegovy? By Region | Curex
Kaiser Permanente Wegovy coverage is regional: CA excludes below BMI 40, NW needs Ozempic trial first, Mid-Atlantic needs 5% loss to renew.
Read moreDoes Medica Cover Wegovy? Upper Midwest Guide 2026 | Curex
Medica covers Wegovy for weight loss only where your employer opts in — formulary not publicly published. Verify via Medica drug lookup. Medicare CV only.
Read moreDoes BCBS of Arizona Cover Wegovy? 2026 Guide | Curex
BCBS of Arizona covers Wegovy only where your employer opted in; formulary not published. Verify via drug-lookup and confirm with HR first.
Read moreDoes Blue Cross Blue Shield Cover Wegovy? 2026 | Curex
BCBS is 33+ independent affiliates — no single Wegovy answer. Trend favors exclusion in 2025-2026. Find your affiliate and verify your formulary.
Read moreDoes Anthem Cover Wegovy? 2026 Coverage Guide | Curex
Anthem covers Wegovy for weight loss only if your employer opts in via CarelonRx, with a 5% renewal rule. Medicare covers the CV indication only.
Read moreWhether or not Molina covers Wegovy, there's a path that skips insurance
You just saw how tangled Wegovy coverage can get — auto-rejections, prior authorization, and high cash prices. Curex compounded semaglutide: $199/month equivalent prepaid annually ($2,388 upfront), or $299/month paid monthly. Compounded tirzepatide: $299/month equivalent prepaid annually ($3,588 upfront), or $399/month paid monthly. Commercial rates as of 2026-10-12; compounded products are not FDA-approved and clinical eligibility must be assessed. Curex compounded medications are not the same as Wegovy. No insurance or prior authorization required; prescription required, subject to provider review.
- Medication + free shipping
- 24/7 provider access
- Medical intake & prescription review
Compounded semaglutide and tirzepatide are not the same medications as Wegovy and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.
This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Molina Healthcare before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Wegovy and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.